[Expert consensus on clinical application of Dieda Qili Tablets in treatment of acute soft tissue injury]

Dieda Qili Tablets are protected traditional Chinese medicine(TCM) variety and type B medicine included in medical insurance in China, which is widely used in the treatment of acute soft tissue injury in clinical practice and has been recommended by many books. However, there is no evidence-based guideline or consensus to guide the clinical application of Dieda Qili Tablets. With the support of China Association of Chinese Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences led the 21 Chinese units to follow the guiding ideology of "evidence as the key, consensus as the supplement, and experience as the reference" to compile this consensus. Interviews and surveys were conducted among a number of clinical experts and front-line doctors across the country, and the clinical problems to be solved were determined through the nominal group method. According to the clinical questions, the evidence of clinical studies was systematically retrieved. The GRADE system was used to evaluate the quality of the evidence, and finally, the recommendation/consensus suggestion was reached through the nominal group method. This consensus clarified the clinical application scope, usage methods, safety, combination medication, and research progress of Dieda Qili Tablets in the treatment of acute soft tissue injury, and it is applicable to clinicians in tertiary hospitals, secondary hospitals, and primary medical and health institutions(TCM, western medicine, and integrated traditional Chinese and western medicine). It provides guidance and refe-rence for the rational use of Dieda Qili Tablets in the treatment of acute soft tissue injury. At present, this consensus has been reviewed and published by the Standardization Office of China Association of Chinese Medicine, with a standard number of GS/CACM 347-2024.